Successful DAA therapy for chronic hepatitis C reduces HLA-DR on monocytes and circulating immune mediators: a long-term follow-up study.,Immunology Letters

当前位置： X-MOL 学术 › Immunol. Lett. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Successful DAA therapy for chronic hepatitis C reduces HLA-DR on monocytes and circulating immune mediators: a long-term follow-up study.
Immunology Letters ( IF 3.3 ) Pub Date : 2020-09-15 , DOI: 10.1016/j.imlet.2020.09.002
Natalia Fonseca Rosário ₁ , Geórgia do Nascimento Saraiva ₁ , Thalia Medeiros ₁ , Mariana Gandini ₂ , Gilmar Lacerda ₃ , Paulo Emílio Corrêa Leite ₄ , Thaís Guaraná Andrade ₅ , Elzinandes Leal Azeredo ₆ , Analúcia Rampazzo Xavier ₃ , Andrea Alice Silva ₃

Affiliation

Introduction

After DAA treatment for chronic hepatitis C infection, peripheral monocyte subsets from patients who achieved sustained virological response (SVR) reduced compared to healthy control. Improvement in inflammatory parameters and liver stiffness has been observed. However, little is known about the long-term impact of DAA treatment on peripheral monocyte subsets and immune mediators levels.

Objectives

We aimed to examine peripheral monocyte subsets and immune mediators levels in Brazilian chronic HCV patients after long-term successful IFN-free SOF-based treatment.

Material and methods

We analyzed CD14++CD16-, CD14++CD16+ and CD14+CD16++ monocytes and 27 immune mediators by flow cytometry and analysis of multiple secreted proteins assay, respectively, in monoinfected chronic HCV patients receiving IFN-free sofosbuvir-based regimens followed before treatment, at SVR and one year after the end of treatment (1y).

Results

Twenty-one biomarkers decreased significantly at 1y and 55–80 % of patients this reduction at 1y. Experimented patients presented a greater modulation of immune mediators at 1y. HLA-DR expression significantly decreased on CD14++CD16- and CD14++CD16+ monocytes at 1y when compared to SVR.

Conclusions

Successful DAA therapy did not modify monocyte subsets frequency but reduced monocyte activation at 1y and sustained the downregulation and restoration of circulating immune mediators, indicating that long-term reversal of inflammation status could occur after HCV eradication.

中文翻译：